Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Oktober 2024

Genmab — Oktober 2024

Planlagt Fastgjort Låst Flyttet Genmab
991 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #817

    JNJ er helt tavs omkring EU patententet eller manglende. Er der nogen der har set selve afgørelsen ?

    1 Reply Last reply
    0
    • G Offline
      G Offline
      gentogen
      wrote on sidst redigeret af
      #818

      Jeg har ledt efter den uden held. Måske mesteren EL kan trylle den frem..., men jeg tror ikke nu ikke, at den er offentliggjort

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #819

        Traverse Biotech to Present Data on ROR2-Targeted T-Cell Engager at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting https://www.prnewswire.com/news-releases/traverse-biotech-to-present-data-on-ror2-targeted-t-cell-engager-at-the-society-for-immunotherapy-of-cancers-sitc-39th-annual-meeting-302286375.html TB-Bs1 is a first-in-class T-cell Engaging (TCE) bispecific antibody built on the DuoBody™ platform targeting ROR2.

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #820

          on HALO ; my understanding is that EPO will send a written form of the decision in a few weeks, JNJ then has ~2 months to appeal. During the appeal the EPO decision is suspended and the patent remains in force. Such an appeal can take ~2 years

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #821

            Maybe we can learn more if we see that EPO write up, I assume that will be public info

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #822

              Third week in a row that the US volume was higher than the Copenhagen volume. I am not sure if we have seen that before

              1 Reply Last reply
              0
              • SolsenS Offline
                SolsenS Offline
                Solsen
                wrote on sidst redigeret af
                #823

                In my opinion it was US that took Genmab down. Would not be surpriced to se them take it up again. Well JNJ has take the uncertainty about their faspro in consideration when they decide the opt. on Erzo. Thanks EL for the link to Traverse Biotech - interesting target for Genmab.

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  bikube
                  wrote on sidst redigeret af
                  #824

                  Kursen i U S plejer at være lidt højere end i DK både på GMAB og Novo.

                  1 Reply Last reply
                  0
                  • L Offline
                    L Offline
                    lahn1
                    wrote on sidst redigeret af
                    #825

                    Dollar er sgu da også højre end danske kroner !. Niveauet er ved at blive lidt for lavt herinde. God weekend 😉

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      bikube
                      wrote on sidst redigeret af
                      #826

                      Lahn - tror du kke, at jeg omregner $ til DKK inden jeg skriver ? Hvis du vil give lidt ekstra, kan du jo købe GMAB i U S.

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #827

                        Bispecific Antibodies, Novel Combinations Highlight Continued Treatment Evolution in Follicular Lymphoma https://www.onclive.com/view/bispecific-antibodies-novel-combinations-highlight-continued-treatment-evolution-in-follicular-lymphoma

                        1 Reply Last reply
                        0
                        • L Offline
                          L Offline
                          lahn1
                          wrote on sidst redigeret af
                          #828

                          Undskyld bikube, den var sagt for sjov. Fortsat god weekend.

                          1 Reply Last reply
                          0
                          • B Offline
                            B Offline
                            bikube
                            wrote on sidst redigeret af
                            #829

                            I orden Lahn.

                            1 Reply Last reply
                            0
                            • Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktør
                              wrote on sidst redigeret af
                              #830

                              Godmorgen 🙂

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                ProinvestorNEWS
                                wrote on sidst redigeret af
                                #831

                                Genmab-investorerne får tirsdag morgen nyt fra Schweiz, hvor Novartis’ regnskab også byder på tal for der også byder på sklerosemidlet Kesimpta, der er udviklet af det danske biotekselskab. Genmab modtager royalties på 10 pct. af salget, der i andet kvartal blev på 799 mio. dollar.

                                1 Reply Last reply
                                0
                                • B Offline
                                  B Offline
                                  bikube
                                  wrote on sidst redigeret af
                                  #832

                                  Er der nogen, der har set tallene fra Novartis ?

                                  1 Reply Last reply
                                  0
                                  • B Offline
                                    B Offline
                                    bikube
                                    wrote on sidst redigeret af
                                    #833

                                    Undskyld - det er i morgen, de kommer.

                                    1 Reply Last reply
                                    0
                                    • exitnuE Offline
                                      exitnuE Offline
                                      exitnu
                                      wrote on sidst redigeret af
                                      #834

                                      Upcoming event: Oct 29, 2024 - Third quarter 2024 results

                                      1 Reply Last reply
                                      0
                                      • G Offline
                                        G Offline
                                        gdn55
                                        wrote on sidst redigeret af
                                        #835

                                        Hu hej hvor det går, med kursen. Forstod ikke hvordan den fik lov til at stige 0,95% i fredags, men pyt nu er vi næsten tilbage, som i torsdag, og imorgen er der atter en dag. Mit store spørgsmål hvor langt ned skal den inden buddet kommer.

                                        1 Reply Last reply
                                        0
                                        • J Offline
                                          J Offline
                                          JKY_VH
                                          wrote on sidst redigeret af
                                          #836

                                          Det ved vist kun JNJ

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper